Establishment Labs Holdings Inc. (NASDAQ:ESTA) Stock Has Average Price Target of $95.00

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been given an average rating of “Moderate Buy” by the ten ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $95.00.

A number of research firms have recently issued reports on ESTA. Stifel Nicolaus initiated coverage on shares of Establishment Labs in a research report on Wednesday, October 14th. They issued a “buy” rating and a $85.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on shares of Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. BTIG Research dropped their price objective on shares of Establishment Labs from $103.00 to $93.00 and set a “buy” rating on the stock in a research note on Thursday, October 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Finally, TD Cowen cut their target price on shares of Establishment Labs from $117.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, October 26th.

Hedge Funds Weigh In On Establishment Labs

Several institutional investors and hedge funds have recently modified their holdings of ESTA. Integrated Wealth Concepts LLC purchased a new stake in shares of Establishment Labs during the second quarter worth $32,000. KBC Group NV purchased a new position in Establishment Labs in the first quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in Establishment Labs in the second quarter valued at about $43,000. Sterling Capital Management LLC grew its stake in Establishment Labs by 849.5% in the third quarter. Sterling Capital Management LLC now owns 902 shares of the company’s stock valued at $58,000 after purchasing an additional 807 shares in the last quarter. Finally, State of Wyoming acquired a new position in Establishment Labs in the 2nd quarter worth about $87,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Stock Up 3.1%

Shares of ESTA stock traded up $2.13 on Tuesday, reaching $70.75. 367,353 shares of the company’s stock traded hands, compared to its average volume of 513,910. The company has a market capitalization of $2.11 billion, a P/E ratio of -55.27 and a beta of 1.03. Establishment Labs has a 12-month low of $53.16 and a 12-month high of $97.59. The company has a debt-to-equity ratio of 17.17, a quick ratio of 2.52 and a current ratio of 3.57. The business’s 50 day moving average price is $66.04 and its two-hundred day moving average price is $72.37.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Friday, October 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.09). Establishment Labs had a negative return on equity of 196.38% and a negative net margin of 14.56%. The business had revenue of $71.99 million during the quarter, compared to analysts’ expectations of $66.81 million. During the same period in the prior year, the company posted ($0.38) earnings per share. The firm’s revenue was up 33.8% on a year-over-year basis. On average, equities analysts forecast that Establishment Labs will post -1.18 earnings per share for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc. is a medical technology company focused on breast health and aesthetics. Founded in 2004 by Juan José Chacón-Quirós, the Costa Rica-based company develops and manufactures products for breast augmentation and reconstruction. Its product portfolio includes Motiva breast implants, offered in different shapes and designs, as well as related technologies and products for plastic and reconstructive surgery. The company also develops solutions intended to support surgical procedures and patient care.